KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Consolidated Net Income (2020 - 2023)

Historic Consolidated Net Income for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.

  • AbCellera Biologics' Consolidated Net Income fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$47.2 million, marking a year-over-year increase of 6348.95%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
  • Latest data reveals that AbCellera Biologics reported Consolidated Net Income of -$47.2 million as of Q4 2023, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
  • AbCellera Biologics' Consolidated Net Income's 5-year high stood at $168.6 million during Q1 2022, with a 5-year trough of -$47.2 million in Q4 2023.
  • Its 4-year average for Consolidated Net Income is $20.5 million, with a median of -$2.5 million in 2020.
  • Data for AbCellera Biologics' Consolidated Net Income shows a peak YoY increase of 570062.11% (in 2021) and a maximum YoY decrease of 69391.01% (in 2021) over the last 5 years.
  • AbCellera Biologics' Consolidated Net Income (Quarter) stood at $161.2 million in 2020, then plummeted by 62.8% to $59.9 million in 2021, then tumbled by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
  • Its Consolidated Net Income stands at -$47.2 million for Q4 2023, versus -$28.6 million for Q3 2023 and -$30.5 million for Q2 2023.